Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.62 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610922 | 1.00 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3ACMSDSOS1 | |
| SCHEMBL84188 | 1.00 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3ACMSDSOS1 | |
| Bromide SCHEMBL7032662 | 0.98 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3ACMSDSOS1 | |
| SCHEMBL1237964 | 0.89 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3ACMSDSOS1 | |
| SCHEMBL875658 | 0.87 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3ACMSDSOS1 | |
| SCHEMBL6883731 | 0.86 | ACMSD (0.55) | SLC6A2SLC6A4SLC6A3ACMSDSOS1 | |
| SCHEMBL27542885 | 0.85 | ACMSD (0.62) | SLC6A2SLC6A4SLC6A3ACMSDSOS1 | |
| SCHEMBL31513836 | 0.84 | SOS1 (0.61) | SLC6A2SLC6A4SLC6A3ACMSDSOS1 | |
| SCHEMBL15780703 | 0.84 | KDM4E (0.64) | SLC6A2SLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL7787046 | 0.84 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3ACMSDSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102133-A1 | MULTIVALENT IONIZABLE LIPID DELIVERY SYSTEMS | FACTOR BIOSCIENCE INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4709364-A1 | THERAPEUTIC FORMULATIONS FOR KIDNEY DISEASE COMPRISING REPAGERMANIUM OR PROPAGERMANIUM AND/OR AT1R BLOCKERS | Dimerix Bioscience Pty Ltd (AU) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705273-A2 | MULTIVALENT IONIZABLE LIPID DELIVERY SYSTEMS | Factor Bioscience Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704880-A1 | VIRAL INFECTION MODULATION IN VACCINATED SUBJECTS TREATED WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) | Partner Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704881-A2 | HUMORAL MODULATION IN VACCINATED AND VIRALLY INFECTED SUBJECTS WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) | Partner Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4665322-A1 | DYSREGULATION OF PLANKTONIC BACTERIAL METABOLISM | Neolixir Limited (AU) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025072659-A2 | EFFECTS OF GM-CSF ADDITION ON HUMORAL MODULATION AND FCGR2B BINDING IN ALLERGY, INFECTION AND IMMUNITY | PARTNER THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025042942-A1 | TRANS-SPLICING SYSTEMS | AMBER BIO INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2025038853-A1 | USHER SYNDROME-RELATED GENE MODIFICATION | AMBER BIO INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4504262-A1 | LONG-ACTING GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR | Partner Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2022204419-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204416-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING VIRAL INFECTIONS INCLUDING COVID-19 AND FOR INFECTION SEVERITY MONITORING AS WELL AS TARGETED DETECTION OF CYTOKINE STORM | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204421-A1 | NATURAL CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204414-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022198264-A1 | TREATMENT OF INFLAMMATORY DISEASES | DIMERIX BIOSCIENCE PTY LTD (AU) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204417-A1 | RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASE DIAGNOSIS AND THERAPY | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-4058441-A1 | ARYL AMINOPYRIMIDINES AS DUAL MERTK AND TYRO3 INHIBITORS AND METHODS THEREOF | The University of North Carolina at Chapel Hill (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-4034109-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF DISEASE | Dimerix Bioscience Pty Ltd (AU) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022125523-A1 | MANUFACTURE OF GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR | PARTNER THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022093671-A1 | GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS | PARTNER THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |